title: Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia.
abstract: Chronic administration of typical antipsychotic agents, which mainly act on the dopamine receptors, implicates a role of dopamine system on the susceptibility of tardive dyskinesia (TD). In the present study, the association between a functional Val158Met polymorphism of Catechol-O-methyltransferase (COMT) gene and TD occurrence and TD severity was investigated in 299 Chinese schizophrenic patients with long-term antipsychotic treatment (TD: 166, non-TD: 133). After adjusting the effects of confounding factors, there was no significant association between COMT genotype and TD occurrence (p=0.367). Among TD patients, we found no significant correlation between COMT genotypes and the total scores of abnormal involuntary movement scale (AIMS) (p=0.629). We concluded that this COMT polymorphism might not play a major role in the susceptibility of TD nor on the severity of TD.
authors.affiliation: Department of Psychiatry, Yuli Veterans Hospital, Tzu Chi University, Hualien, Taiwan.
authors.forename: I-C
authors.initials: IC
authors.lastname: Lai
authors.forename: Y-C
authors.initials: YC
authors.lastname: Wang
authors.forename: C-C
authors.initials: CC
authors.lastname: Lin
authors.forename: Y-M
authors.initials: YM
authors.lastname: Bai
authors.forename: D-L
authors.initials: DL
authors.lastname: Liao
authors.forename: S-C
authors.initials: SC
authors.lastname: Yu
authors.forename: C-Y
authors.initials: CY
authors.lastname: Lin
authors.forename: J-Y
authors.initials: JY
authors.lastname: Chen
authors.forename: Y-J
authors.initials: YJ
authors.lastname: Liou
mesh_terms: D000328:Adult; D019943:Amino Acid Substitution / Q000235:genetics; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001923:Brain Chemistry / Q000187:drug effects* / Q000235:genetics; D002394:Catechol O-Methyltransferase / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D018450:Disease Progression; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000201:enzymology* / Q000235:genetics* / Q000503:physiopathology; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D008715:Methionine / Q000235:genetics; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy; D014633:Valine / Q000235:genetics
chemical_list: D014150:Antipsychotic Agents; D005819:Genetic Markers; D008715:Methionine; D002394:Catechol O-Methyltransferase; D014633:Valine